NCT02609776 2026-04-13CHRYSALISJanssen Research & Development, LLCPhase 1 Active not recruiting751 enrolled 2 FDA
NCT03914612 2026-04-13Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial CancerNational Cancer Institute (NCI)Phase 3 Active not recruiting813 enrolled 16 charts 2 FDA
NCT04538664 2026-04-13PAPILLONJanssen Research & Development, LLCPhase 3 Active not recruiting308 enrolled 12 charts 2 FDA